Almirall's Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults
Shots:
- Ilumetri’s (tildrakizumab) approval is based on the positive results from reSURFACE 1 and 2 P-III clinical trial- testing its safety and efficacy in >200 clinical sites worldwide
- reSURFACE 1 and 2 P-III Results (N=1800): 63% achieved PASI 75@12wks.; ~78% @28 wks.- ~59% achieved PASI 90 and ~30% achieved PASI 100 @28wks.; 92% patients were consistent at PASI 75 while maintaining its tolerability and efficacy
- In 2016- Sun Pharma out-licensed European rights of Ilumetri to Almirall for its development and commercialization for the treatment of psoriasis. Ilumetri is a humanized- anti-IL-23p19 monoclonal Ab- expected to be launched in next few weeks
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
